We used PCR-generated small CRISPR constructs to edit two genes (IDH2 and MYBL2) in hard-to-transfect hemopoietic cells, which are central to the progression of the devastating disease known as acute myeloid leukemia LMA (AML). Here, IDH2 is linked to acute myeloid leukemia.